Siga Technologies (SIGA) Cash from Financing Activities (2010 - 2025)
Siga Technologies (SIGA) posted Cash from Financing Activities of -$403480.0 for Q3 2025, up 99.06% on a QoQ basis from -$42.9 million in Q2 2025, and down 47.18% year-over-year from -$763943.4 in Q3 2024.
Siga Technologies (SIGA) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Siga Technologies' Cash from Financing Activities history runs 16 years deep, the most recent figure standing at -$403480.0 for Q3 2025.
- Quarterly Cash from Financing Activities fell 47.18% year-over-year to -$403480.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$43.6 million (down 0.74% YoY) and the FY2024 annual result came in at -$43.5 million, changed 0.1% from the prior year.
- Cash from Financing Activities was -$403480.0 for Q3 2025 at Siga Technologies, up from -$42.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at -$158980.0 in Q1 2024 and bottomed at -$42.9 million in Q2 2025.
- A 5-year average of -$12.7 million and a median of -$6.6 million in 2021 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 453.31% — and 2024, when it jumped 97.9%.
- Siga Technologies' Cash from Financing Activities stood at -$5.8 million in 2021, then soared by 50.45% to -$2.9 million in 2022, then plunged by 1157.24% to -$35.9 million in 2023, then jumped by 99.55% to -$161756.0 in 2024, then slumped by 149.44% to -$403480.0 in 2025.
- Business Quant data shows SIGA's Cash from Financing Activities at -$403480.0 in Q3 2025, -$42.9 million in Q2 2025, and -$166193.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Siga Technologies | 225.56 Mn | 70.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -403,480.00 |
| Sep 30, 2025 | -403,480.00 |
| Jun 30, 2025 | -42.89 Mn |
| Jun 30, 2025 | -42.89 Mn |
| Mar 31, 2025 | -166,193.00 |
| Mar 31, 2025 | -166,193.00 |
| Dec 31, 2024 | -161,756.00 |
| Dec 31, 2024 | -161,756.00 |
| Sep 30, 2024 | -274,132.00 |
| Sep 30, 2024 | -274,132.00 |
| Jun 30, 2024 | -42.87 Mn |
| Jun 30, 2024 | -42.87 Mn |
| Mar 31, 2024 | -158,980.00 |
| Mar 31, 2024 | -158,980.00 |
| Jun 30, 2023 | -35.87 Mn |
| Jun 30, 2023 | -35.87 Mn |
| Mar 31, 2023 | -7.56 Mn |
| Mar 31, 2023 | -7.56 Mn |
| Dec 31, 2022 | -2.85 Mn |
| Dec 31, 2022 | -2.85 Mn |